Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2476 to 2490 of 7710 results

  1. Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable ID3981

    In development [GID-TA10912] Expected publication date: 16 July 2025

    Technology appraisal guidance
    In development

  2. Vutrisiran for treating transthyretin-related amyloidosis cardiomyopathy [ID6470]

    In development [GID-TA11598] Expected publication date: 12 November 2025

    Technology appraisal guidance
    In development

  3. Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen ID6462

    In development [GID-TA11602] Expected publication date: 11 September 2025

    Technology appraisal guidance
    In development

  4. BI 1015550 for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446]

    Awaiting development [GID-TA11552] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Troriluzole for spinocerebellar ataxia ID 6456

    Awaiting development [GID-TA11549] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Depemokimab for treating chronic rhinosinusitis with nasal polyps ID 6449

    Awaiting development [GID-TA11542] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Transcatheter tricuspid valve replacement for the reduction of tricuspid regurgitation

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  8. Pegzilarginase for treating arginase-1 deficiency [ID4029]

    In development [GID-HST10054] Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  9. Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ]

    In development [GID-HST10060] Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  10. Donidalorsen for preventing hereditary angioedema attacks in people 12 years and over ID6457

    Awaiting development [GID-TA11576] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Lymphoedema: prevention and management in people with early, locally advanced, and advanced breast cancer (update)

    In development [GID-NG10415] Expected publication date: TBC

    NICE guideline
    In development

  12. Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease [ID6405]

    In development [GID-TA11571] Expected publication date: 26 March 2025

    Technology appraisal guidance
    In development

  13. Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker ID 6469

    Awaiting development [GID-TA11575] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Fruquintinib for previously treated metastatic colorectal cancer ID6274

    In development [GID-TA11280] Expected publication date: 05 March 2025

    Technology appraisal guidance
    In development

  15. Brensocatib for treating moderate to severe non-cystic fibrosis bronchiectasis in people 12 years and over ID 6448

    Awaiting development [GID-TA11564] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development